MCID: CHG001
MIFTS: 66

Chagas Disease

Categories: Rare diseases, Infectious diseases, Neuronal diseases

Aliases & Classifications for Chagas Disease

MalaCards integrated aliases for Chagas Disease:

Name: Chagas Disease 12 50 56 52 41 3 14 69
American Trypanosomiasis 12 50 56 3
Chagas' Disease with Digestive System Involvement 12
Chagas' Disease with Nervous System Involvement 12
Chagas' Disease with Other Organ Involvement 12
South American Trypanosomiasis 50
New World Trypanosomiasis 50
Chagas' Disease 12

Characteristics:

Orphanet epidemiological data:

56
american trypanosomiasis
Inheritance: Not applicable; Prevalence: 6-9/10000 (United States); Age of onset: All ages; Age of death: any age;

Classifications:

Orphanet: 56  
Rare infectious diseases


Summaries for Chagas Disease

NIH Rare Diseases : 50 chagas disease is caused by the parasite, trypanosoma cruzi. the triatomine bug, which can carry the parasite, most often bites a person's face and therefore is more commonly known as the "kissing bug". when a triatomine bug infected with trypanosoma cruzi bites, it can leave behind infected waste which can be spread into the person's eyes, nose, or a wound. chagas disease can also spread through contaminated food, a blood transfusion, a donated organ, or from mother to baby during pregnancy. symptoms may include fever, flu-like symptoms, a rash, or swollen eyelid. early symptoms usually go away without treatment, but can last a few weeks or months. however, if not treated in the early phase, the parasite can become active again years later. in fact, 20-30% of infected people will later develop serious problems affecting their heart, intestines, or espophagus. this risk is greater for those with a weakened immune system. chagas disease is common in latin america, but not in the united states. on august 30, 2017, the fda approved benznidazole to treat chagas disease in children between the ages of 2 to 12 years old. nifurtimox may also used to treat chagas disease. although not fda approved, nifurtimox can be obtained for the treatment of chagas disease in the united states through special cdc studies. similarly, benznidazole is also available through special cdc studies for those with chagas disease whose treatment is deemed necessary by their doctor but whose age falls outside fda approval. last updated: 9/18/2017

MalaCards based summary : Chagas Disease, also known as american trypanosomiasis, is related to systemic lupus erythematosus and mucocutaneous leishmaniasis, and has symptoms including diarrhea, headache and hepatomegaly. An important gene associated with Chagas Disease is IL10 (Interleukin 10), and among its related pathways/superpathways are Chagas disease (American trypanosomiasis) and Innate Immune System. The drugs Carvedilol and Enalapril have been mentioned in the context of this disorder. Affiliated tissues include heart, testes and eye, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and cardiovascular system

MedlinePlus : 41 chagas disease is caused by a parasite. it is common in latin america but not in the united states. infected blood-sucking bugs, sometimes called kissing bugs, spread it. when the bug bites you, usually on your face, it leaves behind infected waste. you can get the infection if you rub it in your eyes or nose, the bite wound or a cut. the disease can also spread through contaminated food, a blood transfusion, a donated organ or from mother to baby during pregnancy. if you notice symptoms, they might include fever flu-like symptoms a rash a swollen eyelid these early symptoms usually go away. however, if you don't treat the infection, it stays in your body. later, it can cause serious intestinal and heart problems. a physical exam and blood tests can diagnose it. you may also need tests to see whether the disease has affected your intestines and heart. medicines can kill the parasite, especially early on. you can also treat related problems. for example, a pacemaker helps with certain heart complications. there are no vaccines or medicines to prevent chagas disease. if you travel to areas where it occurs, you are at higher risk if you sleep outdoors or in poor housing conditions. it is important to use insecticides to prevent bites, and practice food safety. centers for disease control and prevention

CDC : 3 Chagas disease is named after the Brazilian physician Carlos Chagas, who discovered the disease in 1909. It is caused by the parasite Trypanosoma cruzi, which is transmitted to animals and people by insect vectors and is found only in the Americas (mainly, in rural areas of Latin America where poverty is widespread). Chagas disease (T. cruzi infection) is also referred to as American trypanosomiasis.

Disease Ontology : 12 A trypanosomiasis that is a tropical parasitic disease caused by the flagellate protozoan Trypanosoma cruzi, which is transmitted to humans and other mammals by an insect vector, the blood-sucking assassin bugs of the subfamily Triatominae (family Reduviidae), most commonly species belonging to the Triatoma, Rhodnius, and Panstrongylus genera. The symptoms include fever, fatigue, body aches, headache, rash, loss of appetite, diarrhea, vomiting, swelling of the eyelids and myocarditis.

Wikipedia : 72 Chagas disease, also known as American trypanosomiasis, is a tropical parasitic disease caused by the... more...

Related Diseases for Chagas Disease

Diseases related to Chagas Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 372)
id Related Disease Score Top Affiliating Genes
1 systemic lupus erythematosus 29.1 CALR CCL2 IFNG IL10 IL2 IL6
2 mucocutaneous leishmaniasis 29.0 CXCL8 IFNG IL10 IL2 NOS2 TLR2
3 malaria 27.6 CCL2 CXCL8 IFNG IL10 IL12B IL1B
4 trypanosomiasis 11.5
5 pure autonomic failure 11.0 IL10 TNF
6 scirrhous adenocarcinoma 10.9 IL2 TNF
7 primary microcephaly-mild intellectual disability-young-onset diabetes syndrome 10.9 IL10 TGFB1
8 acute ackee fruit intoxication 10.9 IL10 TNF
9 spindle cell hemangioma 10.9 IFNG IL10 TNF
10 autoimmune polyglandular syndrome type 3 10.8 IFNG IL2 TNF
11 rickettsialpox 10.8 TLR2 TLR4 TNF
12 graft-versus-host disease, protection against 10.8 IFNG IL10 IL2
13 sternal cleft 10.8 IFNG IL1B TNF
14 psychologic dyspareunia 10.8 IFNG IL10 TNF
15 trichosporonosis 10.8 TLR2 TLR4 TNF
16 bulbospinal polio 10.8 IFNG IL2 TLR4
17 ethmoid sinus adenocarcinoma 10.8 IL10 IL6 TNF
18 parametritis 10.8 IFNG IL2 TNF
19 smarca4-deficient sarcoma of thorax 10.8 IL6 TNF
20 aseptic meningitis 10.8 TLR2 TLR4 TNF
21 hereditary choroidal atrophy 10.8 IFNG TLR2 TLR4
22 strawberry gallbladder 10.8 IFNG IL10 TGFB1
23 idiopathic dilatation of the pulmonary artery 10.8 IL10 NOS2 TNF
24 tonsil cancer 10.8 IFNG IL10 IL1B
25 prothrombin thrombophilia 10.8 IL1B TLR2 TLR4
26 phlyctenulosis 10.8 IL10 IL6 TNF
27 bolivian hemorrhagic fever 10.8 IFNG IL2 TNF
28 basidiobolomycosis 10.8 CXCL8 IL10 TNF
29 primary biliary cirrhosis 10.8 IL10 IL6 TNF
30 ethmoid sinus cancer 10.8 IFNG IL1B TLR4
31 multiple congenital anomalies mental retardation, growth failure and cleft lip palate 10.8 IFNG IL10 IL6
32 ulcerative colitis 10.8 IL10 IL6 TNF
33 eye accommodation disease 10.8 IFNG IL10
34 tarsal tunnel syndrome 10.8 CXCL8 IL10 TNF
35 low compliance bladder 10.8 NOS2 TLR4 TNF
36 membranoproliferative glomerulonephritis 10.7 IFNG IL2 TNF
37 mycobacterium malmoense 10.7 CXCL8 TLR2
38 upper gum cancer 10.7 IL1B IL6 TNF
39 cranial nerve malignant neoplasm 10.7 CCL2 IFNG TGFB1
40 bipolar i disorder 10.7 IL1B IL6 TNF
41 cytomegalovirus disease in patients with impaired cell mediated immunity deemed at risk 10.7 CCL2 IL6 TNF
42 congenital insensitivity to pain with hyperhidrosis 10.7 CXCL8 IL10 TLR4
43 central nervous system leiomyosarcoma 10.7 IL1B IL6 TNF
44 halal setton wang syndrome 10.7 CXCL8 TLR2 TNF
45 indolent myeloma 10.7 IL1B IL6 TNF
46 pityriasis rosea 10.7 IL6 TLR2 TNF
47 loiasis 10.7 IFNG IL10 TGFB1
48 potato nose 10.7 IL6 TGFB1 TNF
49 endogenous depression 10.7 IL2 TLR2 TNF
50 plummer's disease 10.7 IL10 IL6 TNF

Graphical network of the top 20 diseases related to Chagas Disease:



Diseases related to Chagas Disease

Symptoms & Phenotypes for Chagas Disease

Human phenotypes related to Chagas Disease:

56 32 (show all 27)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 diarrhea 56 32 frequent (33%) Frequent (79-30%) HP:0002014
2 headache 56 32 frequent (33%) Frequent (79-30%) HP:0002315
3 hepatomegaly 56 32 frequent (33%) Frequent (79-30%) HP:0002240
4 splenomegaly 56 32 frequent (33%) Frequent (79-30%) HP:0001744
5 thromboembolism 56 32 frequent (33%) Frequent (79-30%) HP:0001907
6 peripheral neuropathy 56 32 very rare (1%) Very rare (<4-1%) HP:0009830
7 encephalitis 56 32 very rare (1%) Very rare (<4-1%) HP:0002383
8 cardiomyopathy 56 32 frequent (33%) Frequent (79-30%) HP:0001638
9 myalgia 56 32 frequent (33%) Frequent (79-30%) HP:0003326
10 dyspnea 56 32 frequent (33%) Frequent (79-30%) HP:0002094
11 arrhythmia 56 32 frequent (33%) Frequent (79-30%) HP:0011675
12 fever 56 32 frequent (33%) Frequent (79-30%) HP:0001945
13 congestive heart failure 56 32 occasional (7.5%) Occasional (29-5%) HP:0001635
14 abdominal pain 56 32 frequent (33%) Frequent (79-30%) HP:0002027
15 cough 56 32 frequent (33%) Frequent (79-30%) HP:0012735
16 lymphadenopathy 56 32 frequent (33%) Frequent (79-30%) HP:0002716
17 achalasia 56 32 occasional (7.5%) Occasional (29-5%) HP:0002571
18 periorbital edema 56 32 frequent (33%) Frequent (79-30%) HP:0100539
19 skin rash 56 32 frequent (33%) Frequent (79-30%) HP:0000988
20 myocarditis 56 32 frequent (33%) Frequent (79-30%) HP:0012819
21 pallor 56 32 frequent (33%) Frequent (79-30%) HP:0000980
22 aganglionic megacolon 56 32 occasional (7.5%) Occasional (29-5%) HP:0002251
23 abnormal large intestine physiology 56 32 occasional (7.5%) Occasional (29-5%) HP:0012700
24 localized skin lesion 56 32 frequent (33%) Frequent (79-30%) HP:0011355
25 autoimmune antibody positivity 56 32 frequent (33%) Frequent (79-30%) HP:0030057
26 edema 56 Frequent (79-30%)
27 abnormality of the nervous system 56 Very rare (<4-1%)

UMLS symptoms related to Chagas Disease:


fever, pruritus

GenomeRNAi Phenotypes related to Chagas Disease according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.77 TNF CXCL8 IL10 IL1B IL2 NOS2
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.77 CXCL8 IL10 IL1B IL2 NOS2 TGFB1

MGI Mouse Phenotypes related to Chagas Disease:

44 (show all 22)
id Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.47 ADRB1 CALR CCR5 CYP51A1 IFNG IL10
2 homeostasis/metabolism MP:0005376 10.43 ADRB1 CALR CCR5 CYP51A1 IFNG IL10
3 immune system MP:0005387 10.39 CCL2 CCR5 CYP51A1 IFNG IL10 IL12B
4 digestive/alimentary MP:0005381 10.38 CCR5 CYP51A1 IFNG IL10 IL12B IL2
5 cellular MP:0005384 10.36 CALR CCR5 IFNG IL10 IL2 IL6
6 growth/size/body region MP:0005378 10.36 IFNG IL10 IL2 IL6 NOS2 SMAD2
7 mortality/aging MP:0010768 10.36 CYP51A1 IFNG IL10 IL12B IL1B IL2
8 hematopoietic system MP:0005397 10.35 CCR5 IFNG IL10 IL12B IL1B IL2
9 behavior/neurological MP:0005386 10.34 CCR5 IFNG IL10 IL2 IL6 NOS2
10 endocrine/exocrine gland MP:0005379 10.26 ADRB1 IFNG IL10 IL2 IL6 NOS2
11 liver/biliary system MP:0005370 10.22 CCR5 IFNG IL10 IL2 IL6 NOS2
12 neoplasm MP:0002006 10.22 CCR5 IFNG IL10 IL12B IL1B IL2
13 muscle MP:0005369 10.21 ADRB1 CALR CCR5 CYP51A1 IFNG IL10
14 integument MP:0010771 10.19 IFNG IL10 IL1B IL6 NOS2 SMAD2
15 craniofacial MP:0005382 10.18 CYP51A1 IFNG IL10 IL12B NOS2 SMAD2
16 adipose tissue MP:0005375 10.15 ADRB1 IL6 NOS2 TGFB1 TLR2 TLR4
17 nervous system MP:0003631 10.15 TGFB1 TLR2 TLR4 TNF CALR CCR5
18 reproductive system MP:0005389 9.96 CCR5 IFNG IL10 IL2 IL6 NOS2
19 no phenotypic analysis MP:0003012 9.92 CYP51A1 IFNG IL10 IL2 SMAD2 TNF
20 respiratory system MP:0005388 9.9 IL12B IL2 IL6 NOS2 SMAD2 TGFB1
21 skeleton MP:0005390 9.77 CYP51A1 IFNG IL10 IL12B IL1B IL6
22 vision/eye MP:0005391 9.32 IL10 IL2 IL6 NOS2 SMAD2 TGFB1

Drugs & Therapeutics for Chagas Disease

Drugs for Chagas Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 71)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
2
Enalapril Approved, Vet_approved Phase 4 75847-73-3 5362032 40466924
3
Enalaprilat Approved Phase 4 76420-72-9 6917719
4
Warfarin Approved Phase 4 81-81-2 6691 54678486
5
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
6 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
7 Antiparasitic Agents Phase 4,Phase 3,Phase 2,Phase 1
8 Antiprotozoal Agents Phase 4,Phase 3,Phase 2,Phase 1
9 Benzonidazole Phase 4,Phase 3,Phase 2
10 Immunosuppressive Agents Phase 4,Phase 3,Phase 2
11 Adrenergic Agents Phase 4,Phase 3
12 Adrenergic alpha-1 Receptor Antagonists Phase 4
13 Adrenergic alpha-Antagonists Phase 4
14 Adrenergic Antagonists Phase 4,Phase 3
15 Adrenergic beta-Antagonists Phase 4,Phase 3
16 Angiotensin-Converting Enzyme Inhibitors Phase 4
17 Antihypertensive Agents Phase 4,Phase 3
18 HIV Protease Inhibitors Phase 4
19 Natriuretic Peptide, Brain Phase 4
20 Neurotransmitter Agents Phase 4,Phase 3
21
protease inhibitors Phase 4
22 Vasodilator Agents Phase 4,Phase 3
23 Anticoagulants Phase 4
24 Peripheral Nervous System Agents Phase 4,Phase 3
25 Analgesics Phase 4
26 Analgesics, Non-Narcotic Phase 4
27 Anti-Inflammatory Agents Phase 4
28 Anti-Inflammatory Agents, Non-Steroidal Phase 4
29 Antipyretics Phase 4
30 Antirheumatic Agents Phase 4
31 Cyclooxygenase Inhibitors Phase 4
32 Fibrinolytic Agents Phase 4
33 Platelet Aggregation Inhibitors Phase 4
34
Coumarin Experimental, Nutraceutical Phase 4 91-64-5 323
35
Bisoprolol Approved Phase 3 66722-44-9 2405
36
Selenium Approved, Vet_approved Phase 3 7782-49-2
37
Amiodarone Approved, Investigational Phase 3 1951-25-3 2157
38
Coal tar Approved Phase 3 8007-45-2
39
Ornithine Approved, Nutraceutical Phase 3 70-26-8, 3184-13-2 6262 389
40 Nifurtimox Investigational Phase 2, Phase 3, Phase 1 23256-30-6
41 Melarsoprol Investigational Phase 3 494-79-1
42 Adrenergic beta-1 Receptor Antagonists Phase 3
43 Autonomic Agents Phase 3
44 Sympatholytics Phase 3
45 Cytochrome P-450 Enzyme Inhibitors Phase 3,Phase 2
46 Antioxidants Phase 3
47 Micronutrients Phase 3
48 Protective Agents Phase 3
49 Sodium Selenite Phase 3
50 Trace Elements Phase 3

Interventional clinical trials:

(show top 50) (show all 60)

id Name Status NCT ID Phase Drugs
1 Optimization of PCR Technique to Assess Parasitological Response for Patients With Chronic Chagas Disease Unknown status NCT01678599 Phase 4 Benznidazole
2 Population Pharmacokinetics Study of Benznidazole in Children With Chagas'Disease Unknown status NCT01549236 Phase 4 Benznidazole 12,5mg or 100mg
3 Population Pharmacokinetics in Benznidazole-treated Adults With Chronic With Chagas Disease Completed NCT01755403 Phase 4 Benznidazole
4 Exercise Training in Chagas Cardiomyopathy Completed NCT01006473 Phase 4
5 A Randomized Trial of Carvedilol in Chronic Chagas Cardiomyopathy Completed NCT01557140 Phase 4 RASi plus carvedilol
6 Outcomes of an Anticoagulation Clinic in an University Hospital Completed NCT01006486 Phase 4
7 Clinical Assessment, Neuroimaging and Immunomarkers in Chagas Disease Study (CLINICS) Recruiting NCT01650792 Phase 4 Aspirin
8 Reveal Chagas: Clinical Evidence of the Implantable Cardiac Monitor in Patients With Chagas Disease Terminated NCT01539161 Phase 4
9 BENEFIT: Evaluation of the Use of Antiparasital Drug (Benznidazole) in the Treatment of Chronic Chagas' Disease Unknown status NCT00123916 Phase 3 Benznidazole;Placebo
10 Etiologic Treatment With Benznidazole in Adult Patients With Chronic Chagas Disease. A Randomized Clinical Trial Completed NCT02386358 Phase 3 Benznidazole;Placebo
11 Physical Exercise Program in Chronic Chagas Heart Disease Completed NCT02517632 Phase 3
12 Cardiac Rehabilitation in Chagas Heart Failure Completed NCT02516293 Phase 2, Phase 3
13 Chagas Cardiomyopathy Bisoprolol Intervention Study: Charity Completed NCT00323973 Phase 3 Bisoprolol
14 Selenium Treatment and Chagasic Cardiopathy (STCC) Recruiting NCT00875173 Phase 3 Selenium;Placebo (for Selenium)
15 CHICAMOCHA 3 - Equivalence of Usual Interventions for Trypanosomiasis (EQUITY) Recruiting NCT02369978 Phase 2, Phase 3 Nifurtimox;Benznidazole;Placebo
16 A Trial Testing Amiodarone in Chagas Cardiomiopathy Recruiting NCT03193749 Phase 3 Amiodarone Hydrochloride;Placebo Oral Tablet
17 Prospective Study of a Pediatric Nifurtimox Formulation for Chagas' Disease Active, not recruiting NCT02625974 Phase 3 Nifurtimox (BAYA2502);Nifurtimox (BAYA2502) followed by Placebo
18 Randomized Clinical Trial of Three Drug Combinations for Late-Stage Gambiense Human African Trypanosomiasis Terminated NCT00330148 Phase 3 melarsoprol 1.8 mg/kg/d, 10d + nifurtimox 15/20 mg/kg/d, 10d;melarsoprol 1.8 mg/kg/d, 10d + eflornithine 400 mg/kg/d, 7d;nifurtimox 15/20 mg/kg/d 10d + eflornithine 400 mg/kg/d 7d
19 Cell Therapy in Chagas Cardiomyopathy Terminated NCT00349271 Phase 3 Filgrastime (G-CSF);Standart therapy
20 Proof-of-Concept Study of E1224 to Treat Adult Patients With Chagas Disease Unknown status NCT01489228 Phase 2 E1224;Benznidazole;Placebo
21 Study to Evaluate Fexinidazole Dosing Regimens for the Treatment of Adult Patients With Chagas Disease Unknown status NCT02498782 Phase 2 Fexinidazole;Placebo
22 A Study of the Use of Oral Posaconazole (POS) in the Treatment of Asymptomatic Chronic Chagas Disease (P05267) Completed NCT01377480 Phase 2 Posaconazole;Placebo for posaconazole;Benznidazole
23 Clinical Trial For The Treatment Of Chronic Chagas Disease With Posaconazole And Benznidazole Completed NCT01162967 Phase 2 Benznidazole;Posaconazole
24 Safety and Efficacy Study of Stem Cell Transplantation to Treat Dilated Cardiomyopathy Completed NCT00629018 Phase 2 Bone Marrow Stimulation
25 Evaluation of Different Benznidazole Regimens for the Treatment of Chronic Chagas Disease. Recruiting NCT03191162 Phase 2 Benznidazole
26 Evaluation of G-CSF (Colony Stimulating Factor) in Patients With Chronic Chagas Cardiomyopathy Enrolling by invitation NCT02154269 Phase 2 Treatment with G-CSF (Granulocyte colony stimulating factor);Placebo saline
27 Study to Assess the Food Effect on the Pharmacokinetics of Nifurtimox Tablets in Chronic Chagas' Patients Completed NCT02606864 Phase 1 Nifurtimox (BAYa2502)
28 Study to Assess Bioequivalence of 30 and 120 mg Nifurtimox Tablets in Chronic Chagas' Patients Completed NCT01927224 Phase 1 Nifurtimox (BAYa2502) (4 x 30 mg tablet);Nifurtimox (BAYa2502) (slurry of 4 x 30 mg tablets in tap water);Nifurtimox (BAYa2502) (120 mg tablet)
29 Prevalence of Chagas Disease in Immigrant Patients With Conduction Abnormalities on Electrocardiogram Unknown status NCT00453700
30 Renal Denervation in Patients With Heart Failure Secondary to Chagas Disease Unknown status NCT02099903
31 Exercise Training in Patients With Chagasic Heart Disease Without Ventricular Dysfunction Unknown status NCT02295215
32 Feasibility of Contact Force Catheter Mapping and Ablation in Epicardial and Endocardial Ventricular Tachycardias Unknown status NCT01847378
33 Improving Blood Safety and HIV Testing in Brazil Unknown status NCT01681420
34 Assessment of Speckle Tracking Strain Predictive Value for Myocardial Fibrosis in Chagas Disease Completed NCT02327052
35 MicroRNAs as Biomarkers in Patients With Chagas Disease Completed NCT01842880
36 Syndecan-4 as a Biomarker in Patients With Chagas Disease Completed NCT01842867
37 Galectin-3 as a Biomarker in Patients With Chagas Disease Completed NCT01842854
38 Population Pharmacokinetics of Benznidazole in Children With Chagas Disease Completed NCT00699387 Benznidazole
39 New Tools for the Diagnosis, Prognosis and Treatment Follow-up in Chagas Disease Completed NCT01755377 Benznidazole
40 Study of Benznidazole Transfer Into Breastmilk in Lactating Women With Chagas Disease Completed NCT01547533
41 Study Of Nifurtimox Transfer Into Breastmilk In Lactating Women With Chagas Disease Completed NCT01744405
42 Chagas Disease Diagnostic - Inconclusive Serology Completed NCT00511589
43 Determination of Genetic Polymorphisms in Chronic Chagas Cardiomyopathy Completed NCT02346123
44 Congenital Transmission of Lineages I and II of Trypanosoma Cruzi Completed NCT01787968
45 Chagas Disease as an Undiagnosed Type of Cardiomyopathy in the United States Completed NCT00005455
46 Longitudinal Study of Patients With Chronic Chagas Cardiomyopathy in Brazil (SaMi_Trop Project) Completed NCT02646943
47 Abbott ESA Chagas Assay Post-Market Study Completed NCT01662362
48 Effect of Ganglionar Electrical Stimulation on Central Arterial Pressure Completed NCT01874795
49 The Signal-averaged ElectrocArdiogram in Long Term Follow-up of Chronic CHagas Disease - RIO de Janeiro Cohort Completed NCT01340963
50 Specificity Study of Diagnostic for Chagas Disease Completed NCT02544139

Search NIH Clinical Center for Chagas Disease

Genetic Tests for Chagas Disease

Anatomical Context for Chagas Disease

MalaCards organs/tissues related to Chagas Disease:

39
Heart, Testes, Eye, Colon, Lymph Node, T Cells, Liver

Publications for Chagas Disease

Articles related to Chagas Disease:

(show top 50) (show all 829)
id Title Authors Year
1
Autochthonous Chagas disease in the southern United States: A case report of suspected residential and military exposures. ( 28418113 )
2017
2
Chagas disease in Europe: A review for the internist in the globalized world. ( 28502864 )
2017
3
Strongyloides stercoralis infection increases the likelihood to detect Trypanosoma cruzi DNA in peripheral blood in Chagas disease patients. ( 28869694 )
2017
4
The Evolutionary Origin of Diversity in Chagas Disease Vectors. ( 27986547 )
2017
5
Sylvatic host associations of Triatominae and implications for Chagas disease reservoirs: a review and new host records based on archival specimens. ( 28948106 )
2017
6
Description of the feeding preferences of triatominae in the Chagas disease surveillance study for the State of Pernambuco, Brazil (Hemiptera: Reduviidae). ( 28954078 )
2017
7
Cardiac inflammation and ventricular tachycardia in Chagas disease. ( 28840107 )
2017
8
Trypanosoma cruzi genetic diversity: Something new for something known about Chagas disease manifestations, serodiagnosis and drug sensitivity. ( 28941731 )
2017
9
Chagas disease and liver transplantation: Experience in Argentina using real-time quantitative PCR for early detection and treatment. ( 28941300 )
2017
10
The Prevalence of Chagas Disease Among Latin American Immigrants with Pacemakers in Los Angeles, California. ( 28500812 )
2017
11
Temporal Variation in the Abundance and Timing of Daily Activity of Chagas Disease Vector Triatoma gerstaeckeri (StAYl, 1859) in a Natural Habitat in the Lower Rio Grande Valley, South Texas. ( 28530845 )
2017
12
Chagas disease in Europe: A long way to go. ( 28951077 )
2017
13
Triatoma vitticeps subcomplex (Hemiptera, Reduviidae, Triatominae): a new grouping of Chagas disease vectors from South America. ( 28407782 )
2017
14
The challenging diagnosis of Chagas disease reactivation in endomyocardial biopsies from heart-transplanted patients. ( 28869079 )
2017
15
Chagas disease immunogenetics: elusive markers of disease progression. ( 28388241 )
2017
16
Understanding transmissibility patterns of Chagas disease through complex vector-host networks. ( 28077180 )
2017
17
Ecological and physiological thermal niches to understand distribution of Chagas disease vectors inA Latin America. ( 28857300 )
2017
18
Chagas Disease: An Important Cause of Megaesophagus in Latin America. ( 28285728 )
2017
19
Access to Chagas disease treatment in non-endemic countries: the case of Spain. ( 28495262 )
2017
20
Regarding Perspective Piece from July 2016 "What Do We Know About Chagas Disease in the United States?" ( 28471741 )
2017
21
Interdisciplinary approach at the primary healthcare level for Bolivian immigrants with Chagas disease in the city of SALo Paulo. ( 28333923 )
2017
22
Transmission of Donor-Derived Trypanosoma cruzi and Subsequent Development of Chagas Disease in a Lung Transplant Recipient. ( 28912986 )
2017
23
Benznidazole approved for Chagas disease in children. ( 28947517 )
2017
24
Etiological Classification of Stroke in Patients with Chagas Disease Using TOAST, Causative Classification System TOAST, and ASCOD Phenotyping. ( 28844546 )
2017
25
Chagas disease: national survey of seroprevalence in children under five years of age conducted in 2008. ( 28443980 )
2017
26
Leishmanicidal and Trypanocidal Activity of Metal Complexes with 1,2,4-Triazolo[1,5-a]pyrimidines: Insights on their Therapeutic Potential against Leishmaniasis and Chagas Disease. ( 28521698 )
2017
27
Evaluation of P2X7 receptor expression in peripheral lymphocytes and immune profile from patients with indeterminate form of Chagas disease. ( 28062289 )
2017
28
The molecular sensory machinery of a Chagas disease vector: expression changes through imaginal moult and sexually dimorphic features. ( 28059141 )
2017
29
Challenges in the management of Chagas disease in Latin-American migrants in Europe. ( 28428122 )
2017
30
The process of lipid storage in insect oocytes: The involvement of I^-chain of ATP synthase in lipophorin-mediated lipid transfer in the chagas' disease vector Panstrongylus megistus (Hemiptera: Reduviidae). ( 27983943 )
2017
31
Risk factors for treatment interruption and severe adverse effects to benznidazole in adult patients with Chagas disease. ( 28949997 )
2017
32
Chagas disease research and development: Is there light at the end of the tunnel? ( 28066534 )
2017
33
Participation of TLR2 and TLR4 in Cytokines Production by Patients with Symptomatic and Asymptomatic Chronic Chagas Disease. ( 27783847 )
2017
34
Ten years of Chagas disease research: Looking back to achievements, looking ahead to challenges. ( 28426735 )
2017
35
Genetic Polymorphisms of IL17 and Chagas Disease in the South and Southeast of Brazil. ( 28470012 )
2017
36
Combined parasitological and molecular-based diagnostic tools improve the detection of Trypanosoma cruzi in single peripheral blood samples from patients with Chagas disease. ( 28954072 )
2017
37
Automated identification of insect vectors of Chagas disease in Brazil and Mexico: the Virtual Vector Lab. ( 28439451 )
2017
38
Correction: Methodological approach to the ex vivo expansion and detection of T. cruzi-specific T cells from chronic Chagas disease patients. ( 28859177 )
2017
39
Development of Diagnostics for Chagas Disease: Where Should We Put Our Limited Resources? ( 28056025 )
2017
40
Molecular and serological detection of Trypanosoma cruzi in dogs (Canis lupus familiaris) suggests potential transmission risk in areas of recent acute Chagas disease outbreaks in Colombia. ( 28532988 )
2017
41
Rapid diagnostic tests duo as alternative to conventional serological assays for conclusive Chagas disease diagnosis. ( 28369081 )
2017
42
Towards Chagas disease elimination: Neonatal screening for congenital transmission in rural communities. ( 28892479 )
2017
43
Biological factors that impinge on Chagas disease drug development. ( 28831944 )
2017
44
Prevalence of Chagas Disease in a U.S. Population of Latin American Immigrants with Conduction Abnormalities on Electrocardiogram. ( 28056014 )
2017
45
Modeling Chagas disease in Chile: From vector to congenital transmission. ( 28435013 )
2017
46
Towards improving early diagnosis of congenital Chagas disease in an endemic setting. ( 28369287 )
2017
47
Unraveling Chagas disease transmission through the oral route: Gateways to Trypanosoma cruzi infection and target tissues. ( 28379959 )
2017
48
Access to benznidazole for Chagas disease in the United States-Cautious optimism? ( 28910299 )
2017
49
Morphology of the spermathecae of twelve species of Triatominae (Hemiptera, Reduviidae) vectors of Chagas disease. ( 28859957 )
2017
50
The Prevalence of Trypanosoma cruzi, the Causal Agent of Chagas Disease, in Texas Rodent Populations. ( 28091763 )
2017

Variations for Chagas Disease

Expression for Chagas Disease

Search GEO for disease gene expression data for Chagas Disease.

Pathways for Chagas Disease

Pathways related to Chagas Disease according to KEGG:

37
id Name Kegg Source Accession
1 Chagas disease (American trypanosomiasis) hsa05142

Pathways related to Chagas Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 89)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
14.18 CALR CCL2 CCR5 CXCL8 IFNG IL10
2
Show member pathways
14 ADRB1 CCL2 CCR5 CXCL8 IL10 IL12B
3
Show member pathways
13.84 CCL2 CCR5 CXCL8 IFNG IL10 IL12B
4
Show member pathways
13.69 CCL2 CXCL8 IFNG IL10 IL12B IL1B
5
Show member pathways
13.6 CCL2 CCR5 CXCL8 IL10 IL12B IL1B
6
Show member pathways
13.54 CCL2 CCR5 CXCL8 IFNG IL10 IL12B
7
Show member pathways
13.47 CCL2 CCR5 CXCL8 IL10 IL12B IL1B
8
Show member pathways
13.15 CCL2 CXCL8 IL1B IL6 NOS2 TLR2
9
Show member pathways
13.11 CALR CCL2 CXCL8 IFNG IL10 IL12B
10
Show member pathways
13.08 CALR CXCL8 IFNG IL10 IL12B IL1B
11
Show member pathways
13.02 CCL2 CXCL8 IFNG IL12B IL1B IL2
12
Show member pathways
12.87 IL1B IL2 IL6 TGFB1 TLR2 TLR4
13
Show member pathways
12.86 CXCL8 IFNG IL12B IL1B IL6 TNF
14
Show member pathways
12.83 CCL2 IFNG IL10 IL12B IL1B IL2
15
Show member pathways
12.8 IFNG IL10 IL12B IL1B IL2 IL6
16 12.76 CXCL8 IL6 NOS2 SMAD2 TGFB1
17 12.74 CCL2 IFNG IL10 IL1B IL2 TLR2
18
Show member pathways
12.72 IFNG IL10 IL12B IL2 TNF
19
Show member pathways
12.7 IL12B IL1B TLR2 TLR4 TNF
20
Show member pathways
12.66 CCR5 IFNG IL10 IL1B IL2 IL6
21 12.61 CALR IL2 IL6 SMAD2 TGFB1 TNF
22
Show member pathways
12.56 CCL2 CXCL8 IFNG IL1B IL6 TLR2
23
Show member pathways
12.5 CXCL8 IFNG IL1B IL6 NOS2 TLR4
24 12.49 IL12B SMAD2 TGFB1 TLR2 TLR4 TNF
25
Show member pathways
12.48 CCR5 IFNG IL10 IL12B IL1B NOS2
26
Show member pathways
12.44 CXCL8 IFNG IL1B IL6 NOS2 TLR2
27 12.43 IFNG IL6 NOS2 SMAD2 TGFB1 TLR2
28 12.43 IFNG IL10 IL12B IL1B IL6 NOS2
29
Show member pathways
12.4 CXCL8 IFNG IL10 IL12B IL1B IL2
30
Show member pathways
12.37 IFNG IL10 IL12B IL2 IL6
31 12.34 CXCL8 IL10 IL1B IL6 TNF
32
Show member pathways
12.22 CCR5 IFNG IL12B IL1B IL2 NOS2
33 12.2 CCL2 IFNG IL1B TNF
34
Show member pathways
12.2 IL10 IL6 SMAD2 TGFB1
35 12.2 CCL2 CXCL8 IL10 IL12B IL1B IL6
36 12.18 IFNG IL10 IL2 IL6 TNF
37 12.16 IFNG IL1B TGFB1 TNF
38 12.16 CCL2 CXCL8 IL1B IL6 SMAD2 TGFB1
39
Show member pathways
12.16 IFNG IL12B IL1B IL6 SMAD2 TGFB1
40 12.16 CXCL8 IFNG IL10 IL12B IL1B IL6
41
Show member pathways
12.15 IL1B IL2 TLR2 TLR4
42 12.13 CXCL8 IFNG IL1B IL6 TGFB1
43
Show member pathways
12.13 IFNG IL10 IL12B IL1B IL2 IL6
44
Show member pathways
12.12 CXCL8 IL12B IL6 SMAD2 TGFB1 TLR4
45 12.11 CCR5 IFNG IL10 IL12B IL2 IL6
46 12.1 CCL2 CXCL8 IFNG IL1B IL2 IL6
47 12.09 CCL2 IL1B IL6 TNF
48 12.08 CXCL8 IFNG IL1B IL6 NOS2 TLR4
49 12.04 IFNG IL6 NOS2 TLR4
50 12.02 CXCL8 IL1B TLR4 TNF

GO Terms for Chagas Disease

Cellular components related to Chagas Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 intracellular GO:0005622 9.87 CALR CCL2 CXCL8 IL2 NOS2 SMAD2
2 cell surface GO:0009986 9.73 CALR CCR5 TGFB1 TLR2 TLR4 TNF
3 extracellular region GO:0005576 9.73 CALR CCL2 CXCL8 IFNG IL10 IL12B
4 external side of plasma membrane GO:0009897 9.63 CALR CCR5 IFNG IL6 TLR4 TNF
5 extracellular space GO:0005615 9.4 CALR CCL2 CXCL8 IFNG IL10 IL12B

Biological processes related to Chagas Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 110)
id Name GO ID Score Top Affiliating Genes
1 regulation of insulin secretion GO:0050796 9.99 IFNG IL1B NOS2 TNF
2 neutrophil chemotaxis GO:0030593 9.99 CCL2 CXCL8 IFNG IL1B
3 positive regulation of inflammatory response GO:0050729 9.99 IL12B IL2 TLR2 TLR4
4 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.98 IFNG IL12B IL2 IL6
5 response to hypoxia GO:0001666 9.98 CCL2 NOS2 TGFB1 TLR2
6 positive regulation of T cell proliferation GO:0042102 9.97 IFNG IL12B IL1B IL2 IL6
7 response to wounding GO:0009611 9.96 CCL2 IL6 TGFB1
8 cellular response to interleukin-1 GO:0071347 9.96 CCL2 CXCL8 IL6
9 chemokine-mediated signaling pathway GO:0070098 9.96 CCL2 CCR5 CXCL8
10 positive regulation of JNK cascade GO:0046330 9.96 IL1B TLR4 TNF
11 humoral immune response GO:0006959 9.96 CCL2 IFNG IL6 TNF
12 response to insulin GO:0032868 9.95 IL10 IL6 TLR2
13 cellular response to drug GO:0035690 9.95 CCL2 IL1B NOS2
14 positive regulation of cell adhesion GO:0045785 9.95 CCL2 IFNG IL12B TNF
15 cellular response to interferon-gamma GO:0071346 9.94 CCL2 IL12B NOS2
16 negative regulation of fat cell differentiation GO:0045599 9.94 IL6 TGFB1 TNF
17 extrinsic apoptotic signaling pathway GO:0097191 9.93 IFNG TGFB1 TNF
18 response to progesterone GO:0032570 9.93 CCL2 TGFB1 TLR2
19 protein kinase B signaling GO:0043491 9.93 CCL2 IL1B TGFB1 TNF
20 cellular response to estradiol stimulus GO:0071392 9.92 CCL2 IL10 IL6
21 cellular response to dexamethasone stimulus GO:0071549 9.92 CCL2 IL6 TGFB1
22 response to bacterium GO:0009617 9.92 CCL2 IL6 NOS2 TLR4
23 negative regulation of mitotic cell cycle GO:0045930 9.91 IL10 TGFB1 TNF
24 positive regulation of phagocytosis GO:0050766 9.91 CALR IL1B TNF
25 positive regulation of interleukin-8 production GO:0032757 9.91 IL1B TLR2 TLR4 TNF
26 positive regulation of tumor necrosis factor production GO:0032760 9.91 CCL2 IFNG IL12B TLR2 TLR4
27 protein import into nucleus, translocation GO:0000060 9.9 IFNG TGFB1 TNF
28 negative regulation of interleukin-6 production GO:0032715 9.9 IL10 TLR4 TNF
29 positive regulation of interleukin-12 production GO:0032735 9.9 IFNG IL12B TLR2 TLR4
30 immune response GO:0006955 9.9 CCL2 CCR5 CXCL8 IFNG IL10 IL1B
31 positive regulation of protein complex assembly GO:0031334 9.89 IFNG TGFB1 TNF
32 positive regulation of interleukin-10 production GO:0032733 9.89 IL12B TLR2 TLR4
33 positive regulation of osteoclast differentiation GO:0045672 9.89 IFNG IL12B TNF
34 positive regulation of interleukin-6 production GO:0032755 9.89 IL1B IL6 TLR2 TLR4 TNF
35 cellular response to mechanical stimulus GO:0071260 9.88 IL1B TGFB1 TLR4
36 defense response to protozoan GO:0042832 9.88 IFNG IL10 IL12B IL6
37 positive regulation of nitric oxide biosynthetic process GO:0045429 9.88 IFNG IL1B IL6 TLR4 TNF
38 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.87 IFNG IL1B TNF
39 response to lipopolysaccharide GO:0032496 9.87 CCL2 IL10 IL1B IL6 NOS2 TLR2
40 positive regulation of nitric-oxide synthase biosynthetic process GO:0051770 9.85 CCL2 TLR2 TLR4
41 positive regulation of interferon-gamma production GO:0032729 9.85 IL12B IL1B IL2 TLR4 TNF
42 positive regulation of interleukin-17 production GO:0032740 9.84 IL12B IL2 TGFB1
43 response to molecule of bacterial origin GO:0002237 9.84 CXCL8 IL10 TLR2
44 positive regulation of chemokine production GO:0032722 9.84 IL6 TLR2 TLR4 TNF
45 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.83 IL10 IL1B TNF
46 negative regulation of growth of symbiont in host GO:0044130 9.83 IFNG IL10 IL12B TNF
47 positive regulation of chemokine biosynthetic process GO:0045080 9.82 IFNG IL1B TNF
48 response to cholesterol GO:0070723 9.81 CCR5 SMAD2 TGFB1
49 positive regulation of MHC class II biosynthetic process GO:0045348 9.81 IFNG IL10 TLR4
50 T-helper 1 type immune response GO:0042088 9.79 IL12B TLR4

Molecular functions related to Chagas Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 receptor binding GO:0005102 9.62 CCL2 IL6 NOS2 NPPB
2 protein heterodimerization activity GO:0046982 9.55 ADRB1 IL12B SMAD2 TGFB1 TLR2
3 type I transforming growth factor beta receptor binding GO:0034713 9.37 SMAD2 TGFB1
4 growth factor activity GO:0008083 9.35 IL10 IL12B IL2 IL6 TGFB1
5 cytokine activity GO:0005125 9.32 CCL2 CXCL8 IFNG IL10 IL12B IL1B
6 lipopolysaccharide receptor activity GO:0001875 9.26 TLR2 TLR4

Sources for Chagas Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....